Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma
HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy
Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions
<scp>Tumor‐infiltrating</scp> lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer
Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Neurologic complications of immune checkpoint inhibitors
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Predictors of responses to immune checkpoint blockade in advanced melanoma